FDA grants breakthrough designation for Anumana’s ECG-AI algorithm
Related Articles
Anumana Appoints Harry S. Palmin as CFO
Anumana Appoints Harry S. Palmin as CFOCAMBRIDGE, Mass. – May 14, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…May 14, 2024
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 15, 2022
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push
Med City News: Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a…May 08, 2021